Executive Summary

The global medical technology landscape is undergoing accelerated change. As governments and providers intensify pressure on pricing, care delivery shifts to lower-cost settings, and supply chains face geopolitical and economic volatility, medtech companies must rethink long-held assumptions about competitiveness. By 2026, the sector will be defined by five interconnected trends: the expanding influence of Mainland China's volume-based procurement (VBP), the continued migration of procedures to outpatient and ambulatory surgical centers (ASCs), the strategic imperative of supply chain resilience, the clinical and commercial ripple effects of GLP-1 receptor agonists, and the emergence of platform-based competition driven by enabling technologies. These developments are not isolated; they collectively signal a fundamental reset in how medical devices are priced, produced, and positioned.

Introduction

For decades, medical technology companies competed primarily on product innovation and clinical evidence. Today, that calculus is being complicated by external forces: policy levers that directly shape market access, reimbursement frameworks that reward cost efficiency, and technology architectures that extend beyond single devices. The result is an industry where commercial success demands a portfolio-level strategy, operational agility, and deep integration with care-delivery ecosystems. This article examines the principal medtech trends expected to define 2026, drawing on industry analysis and market intelligence.

Business Context

The medtech sector operates at the intersection of healthcare, technology, and global trade. Its growth has historically been driven by demographic demand, clinical advancement, and the diffusion of innovations across borders. However, the current environment is marked by rising input costs, fiscal restraint among payers, and industrial policies aimed at nurturing domestic manufacturing. In this context, the ability to navigate regulatory and procurement shifts is becoming as critical as the ability to develop breakthrough products.

Five Forces Reshaping Medtech in 2026

1. Mainland China's VBP Expansion Redefines Global Market Economics

Mainland China's national volume-based procurement program, originally designed to expand patient access and lower device costs, has evolved into a powerful market-structuring mechanism. The latest procurement round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, VBP is no longer a localized policy issue; it influences pricing expectations and competitive positioning across multiple markets.

The strategic implications are significant. Global companies must decide where to compete in the world's second-largest healthcare market, balancing volume opportunities against margin pressures. Meanwhile, the program's support for domestic innovation is expected to accelerate the rise of local champions, altering the competitive landscape in China and potentially in other emerging markets.

2. Outpatient and ASC Settings Become Central to Procedure Strategy

Regulatory changes in the United States are reinforcing a long-running shift of procedures from hospital inpatient settings to outpatient departments and ambulatory surgical centers. The Centers for Medicare & Medicaid Services' 2026 payment rules expand the ASC Covered Procedure List and phase out the inpatient-only list, making higher-acuity procedures such as cardiac ablation eligible for reimbursement in lower-cost settings.

This transformation carries commercial implications for medical device manufacturers. Product design, sales force structure, and economic value propositions must align with the needs of ASCs, which prioritize efficiency, ease of use, and cost transparency. For therapy areas like orthopedics and general surgery, ASCs are already central to growth strategies; the trend is likely to extend to cardiovascular and other complex procedures.

3. Global Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Tariff exposure, geopolitical friction, and fluctuating material costs are challenging assumptions about where and how medical devices should be produced. In response, companies are diversifying suppliers, re-evaluating manufacturing footprints, and investing in multi-region production capabilities. Larger manufacturers are leveraging scale and vertical integration to buffer against volatility, potentially widening the competitive gap between large and mid-sized players.

The strategic emphasis is shifting from cost optimization alone to resilience and flexibility. Supply chain design is becoming a board-level issue, as executives recognize that disruptions to component availability or production location can have immediate revenue and reputational consequences.

4. GLP-1 Therapies Alter Patient Behavior and Care Pathways

The rapid adoption of GLP-1 receptor agonists for weight management is changing how patients and clinicians approach metabolic disease. While bariatric surgery remains the most effective intervention for substantial weight loss, the popularity of GLP-1s is affecting referral patterns and procedure volumes across adjacent categories. Some bariatric procedures are experiencing sharper demand pressure than others, and downstream effects are emerging in areas such as diabetes care, sleep apnea, and cardiovascular monitoring.

For medtech companies, the GLP-1 effect underscores the importance of monitoring cross-sector dynamics. Decisions made outside the device industry — in pharmaceutical development and primary care — can reshape device market opportunities. Companies must consider scenario planning that accounts for continued GLP-1 uptake and its long-term impact on procedure mix.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts to procedures; they are becoming the foundation of integrated clinical ecosystems. Companies are investing in platform architectures that span preoperative planning, intraoperative execution, and postoperative care, creating deeper customer engagement and data-driven value propositions. Emerging open-platform systems are also expanding flexibility, enabling interoperability with existing hospital infrastructure.

This trend redefines competitive advantage. Device differentiation increasingly depends on software integration, ecosystem partnerships, and the ability to generate actionable insights from procedural data. Medtech companies are competing less as product suppliers and more as strategic partners in care delivery transformation.

Commercial Impact

The trends outlined above will affect multiple dimensions of commercial strategy. Pricing models must accommodate VBP-style procurement mechanisms in various markets. Sales and marketing approaches need to adapt to ASC decision-making dynamics. Manufacturing strategies must balance cost, risk, and agility. Product portfolios should be evaluated not only for clinical efficacy but also for resilience to therapy substitution and regulatory shifts.

For investors and corporate planners, the medtech sector presents a mixed outlook. Growth is likely to be concentrated in areas aligned with outpatient care, enabling technology platforms, and companies with diversified manufacturing footprints. Firms heavily exposed to inpatient procedures or markets with aggressive price controls may face margin compression.

Strategic Insights

Leaders should consider several strategic responses. First, portfolio rationalization: divesting from commoditized segments while investing in high-growth areas such as robotics, digital health, and metabolic-focused devices. Second, regionalization: building flexible supply chains that combine scale with proximity to key markets. Third, partnership development: collaborating with software providers, data analytics firms, and care-delivery organizations to offer comprehensive solutions rather than standalone products.

Moreover, the rise of platform-based competition means that companies must think in terms of ecosystems. This may require building open interfaces, acquiring digital capabilities, or forming alliances with competitors to broaden market access. The ability to manage complexity and integrate across technology layers will be a key differentiator.

Future Outlook

Looking ahead to the next three to ten years, the medtech industry is likely to see continued convergence with digital technology and a deeper focus on value-based care. Artificial intelligence and data analytics will increasingly guide clinical decisions, optimize procedural workflows, and enable personalized treatment pathways. The shift toward outpatient and alternative care sites is expected to accelerate, driven by payment reforms and patient preference. Meanwhile, global trade dynamics will remain fluid, prompting companies to maintain supply chain agility as a permanent capability.

The VBP model may expand beyond Mainland China to other countries seeking cost containment, requiring multinationals to develop flexible pricing frameworks. GLP-1 therapies and other pharmaceutical innovations will continue to reshape disease management, with device manufacturers needing to monitor and adapt to changing clinical patterns. In this environment, long-term competitiveness will depend on strategic foresight, operational resilience, and the ability to harness enabling technologies for value creation.

Conclusion

As 2026 approaches, medtech industry trends point toward a more complex and demanding environment. The firms that succeed will be those that treat these forces not as isolated risks but as interconnected drivers of strategic change. By aligning product portfolios, supply chains, commercial models, and technology investments with the new realities of global pricing, outpatient care, and platform-based competition, medtech companies can position themselves for sustainable growth in an era of transformation.

Sources

• Clarivate, "5 medtech trends to watch in 2026" - https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026